European Commission logo
español español
CORDIS - Resultados de investigaciones de la UE
CORDIS

The critical shift to single-cell formats in functional analyses of living cells

Objetivo

The incredible potential of cell and immune therapy (CIT) is limited by technical challenges related to the standard analysis of immune cells in bulk, which neglects their heterogeneity. Single-cell functional resolution is essential to understand the full potential of immune cells. Current single-cell technologies are limited, low-throughput, high-cost and lack robustness, prohibitive for their implementation in CIT R&D, manufacturing and patient stratification. Samplix is developing Xplore, an all-in-one multiparameter single-cell analyser and sorter for screening, selection and expansion of immune cells based on functionality and potency. Xplore is a cost-effective solution that delivers higher throughput and sensitivity than current solutions, being compatible with CIT research workflows. Unlocking the full potential of CIT supports the faster and efficient development of new personalized therapies to treat serious diseases such as cancer, autoimmune diseases, and viral infections.

Coordinador

SAMPLIX ApS
Aportación neta de la UEn
€ 2 500 000,00
Dirección
BREGNERODVEJ 96
3460 Birkerod
Dinamarca

Ver en el mapa

Pyme

Organización definida por ella misma como pequeña y mediana empresa (pyme) en el momento de la firma del acuerdo de subvención.

Región
Danmark Hovedstaden Nordsjælland
Tipo de actividad
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Enlaces
Coste total
€ 4 926 042,50